|
Free
Eli Lilly & Co. enters mid‑2026 in a position of extraordinary financial strength, defined by the ascendance of its incretin franchise—specifically Mounjaro and Zepbound—which now constitutes the
|
Free
Backed by 238 corroborating sources, the evidence for Meta's shift from internal AI to external cloud services is overwhelming.
|
Free
Why history’s infrastructure lesson explains Microsoft’s strategic consolidation across the AI stack
|
Free
Lilly's dual-incretin leads a consolidated market, yet APAC access remains uncertain.
|
Free
Tracing the cost curve from fabrication yields to billing surprises, revealing the tightening margin for cloud customers.
|
Free
Tirzepatide fuels 80% revenue surge even as two-thirds of sales concentrate in one therapy.
|
Free
Microsoft, Amazon, and Google pour $725B into data centers, mirroring the great railroad and steel expansions.
|
Free
How Microsoft is building an integrated industrial base for the AI economy, capturing margins at every layer.
|
Free
Zepbound's 80% revenue jump signals upside, but access and supply cap the bull case.